Need professional-grade analysis? Visit stockanalysis.com
$65.93M
N/A
N/A
N/A
Dogwood Therapeutics, Inc. (DWTX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.53, up 0.33% from the previous close.
Over the past year, DWTX has traded between a low of $1.52 and a high of $7.91. The stock has lost 73.9% over this period. It is currently 80.7% below its 52-week high.
Dogwood Therapeutics, Inc. has a market capitalization of $65.93M.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2020 and is based in Alpharetta, Georgia.
Side-by-side comparison against top Healthcare peers.